BIOASTER announces the kick off a new IMI project “GNA NOW” (Gram-Negative Antibacterials NOW), led by Evotec SE, managed by Lygature and funded by the Innovative Medicines Initiative (IMI), a public-private european R&D consortium.
The program will work on the development of novel antibacterial agents to battle antimicrobial resistance in gram-negative bacteria.
The multi-stakeholder consortium includes 9 other partners from academia, industry and SMEs: Nosopharm, BIOASTER, Helmholtz Centre for Infection Research, North Bristol National Health Service Trust, University of Liverpool, Inserm, Erasmus Medical Center, Medical University of Vienna, and Fraunhofer IME.
More information on the press release here.